NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
26.67
-1.16 (-4.17%)
At close: Aug 13, 2026, 4:00 PM EDT
27.20
+0.53 (1.99%)
After-hours: Aug 13, 2026, 7:34 PM EDT
NewAmsterdam Pharma Company Employees
NewAmsterdam Pharma Company had 100 employees as of December 31, 2025. The number of employees increased by 32 or 47.06% compared to the previous year.
Employees
100
Change
32
Growth
47.06%
Revenue / Employee
$71,210
Profits / Employee
-$2,595,040
Market Cap
3.19B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 100 | 32 | 47.06% |
| Mar 31, 2025 | 77 | 37 | 92.50% |
| Dec 31, 2024 | 68 | 39 | 134.48% |
| Sep 30, 2024 | 62 | 40 | 181.82% |
| Jun 30, 2024 | 57 | 35 | 159.09% |
| Mar 31, 2024 | 40 | 23 | 135.29% |
| Dec 31, 2023 | 29 | 12 | 70.59% |
| Jun 30, 2023 | 22 | - | - |
| Dec 31, 2022 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Iovance Biotherapeutics | 975 |
| AbCellera Biologics | 562 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Immunome | 247 |
| Alumis | 227 |
| uniQure | 221 |
NAMS News
- 8 days ago - NewAmsterdam Pharma Company Transcript: Investor Day 2026 - Transcripts
- 8 days ago - NewAmsterdam Pharma Company Slides: FY 2026 - Filings
- 8 days ago - NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewsWire
- 8 days ago - NewAmsterdam Pharma Company Quarterly report: Q2 2026 - Filings
- 8 days ago - NewAmsterdam Pharma Company Earnings release: Q2 2026 - Filings
- 15 days ago - NewAmsterdam Pharma to Host Investor Day on August 5, 2026 - GlobeNewsWire
- 20 days ago - NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - GlobeNewsWire
- 6 weeks ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire